title: [Efficacy observation of (125)I seed implantation therapy for locoregional recurrent and metastatic breast cancer].
abstract: OBJECTIVE
  To assess the efficacy and side effects of (125)I seed implantation for locoregional recurrent and metastatic breast cancer, and to discuss its role in the comprehensive therapy of breast cancer.
  
  
  METHODS
  Forty-three patients with locoregional recurrent or metastatic breast cancer were included in this study. They received (125)I seed implantation and were followed up to evaluate the efficacy and adverse reactions of the treatment.
  
  
  RESULTS
  Among 54 lesions in the 43 cases, there were complete response (CR) in 39, partial response (PR) in 13, stable disease (SD) in 2 patients, with a response rate of 96.3%. All 17 cases with local pain achieved pain relief. With a median follow up of 36 months (range 14 to 60 months), the 1-, 3-, and 5-year local control rate was 85.2%, 53.7% and 1.9%, and the 1-, 3-, and 5-year survival rate was 95.3%, 67.4% and 37.2%, respectively. No serious radiotherapy side effect was observed.
  
  
  CONCLUSIONS
  In patients with unresectable locoregional recurrent or metastatic breast cancer, (125)I seed implantation shows proved efficacy and few complications, and can be an important treatment option.
authors.affiliation: Department of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: F X
authors.initials: FX
authors.lastname: Yi
authors.affiliation: Department of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: Y H
authors.initials: YH
authors.lastname: Yu
authors.affiliation: Department of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: C Y
authors.initials: CY
authors.lastname: Wei
authors.affiliation: Department of Ultrasound Diagnosis, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: W P
authors.initials: WP
authors.lastname: Yang
authors.affiliation: Department of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: Q H
authors.initials: QH
authors.lastname: Qin
authors.affiliation: Department of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: Q X
authors.initials: QX
authors.lastname: Tan
authors.affiliation: Department of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: Q G
authors.initials: QG
authors.lastname: Mo
authors.affiliation: Department of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Huang
authors.affiliation: Department of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University, Nanning 530021, China.
authors.forename: B
authors.initials: B
authors.lastname: Lian
mesh_terms: D001918:Brachytherapy; D001943:Breast Neoplasms / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009362:Neoplasm Metastasis / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D059408:Pain Management; D015996:Survival Rate
chemical_list: D007457:Iodine Radioisotopes